Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALTS NASDAQ:ANEB NASDAQ:PMN NASDAQ:STTK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTSALT5 Sigma$4.18+5.3%$6.51$1.55▼$10.95$90.33M1.9114.89 million shs6.48 million shsANEBAnebulo Pharmaceuticals$2.37+17.9%$2.37$0.80▼$3.42$97.37M-0.89125,346 shs1.00 million shsPMNPromis Neurosciences$0.44+5.2%$0.59$0.38▼$1.59$22.79M-0.053.12 million shs531,191 shsSTTKShattuck Labs$1.92-3.0%$1.00$0.69▼$3.95$91.97M1.641.54 million shs252,083 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTSALT5 Sigma0.00%-4.78%-42.02%-59.26%+80.17%ANEBAnebulo Pharmaceuticals0.00%-0.42%-2.87%+70.50%+33.90%PMNPromis Neurosciences0.00%+2.30%-30.17%-15.32%-64.24%STTKShattuck Labs0.00%+23.87%+123.15%+90.10%-48.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTSALT5 Sigma$4.18+5.3%$6.51$1.55▼$10.95$90.33M1.9114.89 million shs6.48 million shsANEBAnebulo Pharmaceuticals$2.37+17.9%$2.37$0.80▼$3.42$97.37M-0.89125,346 shs1.00 million shsPMNPromis Neurosciences$0.44+5.2%$0.59$0.38▼$1.59$22.79M-0.053.12 million shs531,191 shsSTTKShattuck Labs$1.92-3.0%$1.00$0.69▼$3.95$91.97M1.641.54 million shs252,083 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTSALT5 Sigma0.00%-4.78%-42.02%-59.26%+80.17%ANEBAnebulo Pharmaceuticals0.00%-0.42%-2.87%+70.50%+33.90%PMNPromis Neurosciences0.00%+2.30%-30.17%-15.32%-64.24%STTKShattuck Labs0.00%+23.87%+123.15%+90.10%-48.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTSALT5 Sigma 0.00N/AN/AN/AANEBAnebulo Pharmaceuticals 2.50Moderate Buy$5.50132.07% UpsidePMNPromis Neurosciences 3.00Buy$4.33885.07% UpsideSTTKShattuck Labs 2.86Moderate Buy$4.00108.33% UpsideCurrent Analyst Ratings BreakdownLatest PMN, ANEB, STTK, and ALTS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025STTKShattuck LabsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$4.008/14/2025STTKShattuck LabsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$4.00 ➝ $2.008/14/2025STTKShattuck LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold7/23/2025ANEBAnebulo PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/21/2025PMNPromis NeurosciencesLeede FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy7/14/2025PMNPromis NeurosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$4.007/14/2025PMNPromis NeurosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$4.00(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTSALT5 Sigma$12.53M7.21N/AN/A$0.49 per share8.53ANEBAnebulo PharmaceuticalsN/AN/AN/AN/A$0.15 per shareN/APMNPromis NeurosciencesN/AN/AN/AN/A$0.50 per shareN/ASTTKShattuck Labs$5.72M16.08N/AN/A$1.67 per share1.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTSALT5 Sigma-$6.24MN/A0.00∞N/A-74.89%-179.27%-16.28%N/AANEBAnebulo Pharmaceuticals-$8.20M-$0.26N/A∞N/AN/A-90.11%-84.53%9/24/2025 (Estimated)PMNPromis Neurosciences$2.78M-$0.210.00N/AN/AN/A-266.69%-131.59%11/13/2025 (Estimated)STTKShattuck Labs-$75.41M-$1.21N/AN/AN/AN/A-81.80%-71.46%11/13/2025 (Estimated)Latest PMN, ANEB, STTK, and ALTS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/24/2025Q4 2025ANEBAnebulo Pharmaceuticals-$0.05N/AN/AN/AN/AN/A8/14/2025Q2 2025STTKShattuck Labs-$0.25-$0.24+$0.01-$0.24N/AN/A8/13/2025Q2 2025PMNPromis Neurosciences-$0.22-$0.29-$0.07-$0.29N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTSALT5 SigmaN/AN/AN/AN/AN/AANEBAnebulo PharmaceuticalsN/AN/AN/AN/AN/APMNPromis NeurosciencesN/AN/AN/AN/AN/ASTTKShattuck LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTSALT5 Sigma1.450.880.88ANEBAnebulo PharmaceuticalsN/A25.2925.29PMNPromis NeurosciencesN/A0.970.97STTKShattuck LabsN/A10.2510.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTSALT5 Sigma6.27%ANEBAnebulo Pharmaceuticals28.40%PMNPromis Neurosciences50.13%STTKShattuck Labs58.74%Insider OwnershipCompanyInsider OwnershipALTSALT5 Sigma4.90%ANEBAnebulo Pharmaceuticals80.60%PMNPromis Neurosciences6.11%STTKShattuck Labs12.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTSALT5 Sigma17021.61 million20.55 millionN/AANEBAnebulo Pharmaceuticals441.08 million7.97 millionNot OptionablePMNPromis Neurosciences551.81 million48.64 millionNot OptionableSTTKShattuck Labs10047.90 million42.16 millionOptionablePMN, ANEB, STTK, and ALTS HeadlinesRecent News About These CompaniesShattuck Labs (NASDAQ:STTK) Upgraded at Wall Street ZenSeptember 14 at 3:55 AM | americanbankingnews.comShattuck Labs, Inc. (NASDAQ:STTK) Receives $4.00 Average Price Target from BrokeragesSeptember 13 at 3:17 AM | americanbankingnews.comQ3 Earnings Forecast for Shattuck Labs Issued By WedbushSeptember 12 at 8:20 AM | marketbeat.comQ3 Earnings Estimate for Shattuck Labs Issued By WedbushSeptember 11 at 2:18 AM | americanbankingnews.comShattuck Labs (NASDAQ:STTK) Coverage Initiated by Analysts at WedbushSeptember 10, 2025 | marketbeat.comShattuck Labs, Inc. (NASDAQ:STTK) Given Average Rating of "Moderate Buy" by AnalystsSeptember 10, 2025 | marketbeat.comWedbush Initiates Coverage on Shattuck Labs (NASDAQ:STTK)September 10, 2025 | americanbankingnews.comWedbush Initiates Coverage of Shattuck Labs (STTK) with Outperform RecommendationSeptember 9, 2025 | msn.comShattuck Labs (STTK) Upgraded to Buy: What Does It Mean for the Stock?September 8, 2025 | zacks.comWall Street Zen Upgrades Shattuck Labs (NASDAQ:STTK) to "Hold"September 8, 2025 | marketbeat.comShattuck Labs (NASDAQ:STTK) Stock Rating Upgraded by Wall Street ZenSeptember 7, 2025 | americanbankingnews.comShort Interest in Shattuck Labs, Inc. (NASDAQ:STTK) Grows By 196.4%September 6, 2025 | americanbankingnews.comShattuck Labs (NASDAQ:STTK) Director Orbimed Advisors Llc Purchases 6,306,127 Shares of StockSeptember 3, 2025 | americanbankingnews.comShattuck Labs (NASDAQ:STTK) Director Mona Ashiya Buys 6,306,127 SharesSeptember 3, 2025 | insidertrades.comOrbiMed Advisors buys Shattuck Labs (STTK) shares worth $5.47 millionSeptember 3, 2025 | investing.comAshiya Mona buys Shattuck Labs (STTK) shares worth $5.47 millionSeptember 3, 2025 | investing.comShattuck Labs Closes $103M Private Placement DealAugust 26, 2025 | msn.comShattuck Labs Secures $103 Million in Private Placement to Advance SL-325 for Autoimmune Diseases and Appoints New Board MembersAugust 26, 2025 | quiverquant.comQShattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of DirectorsAugust 26, 2025 | globenewswire.comShattuck Labs, Inc.: Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel DiseaseAugust 22, 2025 | finanznachrichten.deShattuck Labs says IND for SL-325 for treatment of IBD in effectAugust 22, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePMN, ANEB, STTK, and ALTS Company DescriptionsALT5 Sigma NASDAQ:ALTS$4.18 +0.21 (+5.29%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$4.10 -0.09 (-2.03%) As of 09/12/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.Anebulo Pharmaceuticals NASDAQ:ANEB$2.37 +0.36 (+17.91%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.34 -0.03 (-1.27%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.Promis Neurosciences NASDAQ:PMN$0.44 +0.02 (+5.24%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.42 -0.02 (-4.30%) As of 09/12/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Shattuck Labs NASDAQ:STTK$1.92 -0.06 (-3.03%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.86 -0.05 (-2.86%) As of 09/12/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
